TOLLYS

TOLLYSis a lyonbiopole member

General information

60 F avenue Rockefeller

69008 LYON 08

Incorporated in: 2015/07/02

Number of employees: 13

 

Main activity

TOLLYS develops new ligands of Toll Like Receptor 3 (TLR3)as specific immunotherapies with immunological induced memory in the field of cancer (personnalized vaccines). TOLLYS is actually seeking for funds to perform preclincal studies and go through phase I clinical study.


Funding

Looking for funding: Yes

Nature of funding searches: Yes

Segmentation
Activities

Strategic area of application
Human Medicine


Application market
Oncology


Activities
Therapeutics, Pharma or Biotech


Technologies
Vaccine - Molecular Biology and Nucleic acid